Syncom Formulations Reports FY26 Audited Results: Standalone Profit at ₹2457.42 Lakhs
Syncom Formulations reported FY26 audited results. Standalone profit after tax was ₹7,600.80 lakhs (year-ended) and ₹2,457.42 lakhs (Q4). Consolidated profit after tax was ₹7,643.80 lakhs (year-ended) and ₹2,517.44 lakhs (Q4). The company updated its EPS calculation methodology.
The financial results show positive growth, which is material for investors. The restatement of EPS is a procedural update but the core financial performance is positive.
The company reported growth in both standalone and consolidated revenue and profit for the year ended March 31, 2026, compared to the previous year. The auditors' report was also unmodified.
Syncom Formulations (India) Limited announced its audited financial results for the quarter and year ended March 31, 2026. The company's Board of Directors approved the standalone and consolidated financial results, along with the auditors' report, statement of assets and liabilities, and cash flow statement.
For the standalone results, the total income for the year ended March 31, 2026, stood at ₹14,822.86 lakhs, an increase from ₹12,007.44 lakhs in the previous year. Profit after tax for the year was ₹7,600.80 lakhs, compared to ₹4,887.18 lakhs in the prior year. For the quarter ended March 31, 2026, standalone profit after tax was ₹2,457.42 lakhs.
The consolidated results also showed growth, with total income for the year reaching ₹52,051.14 lakhs. Consolidated profit after tax for the year was ₹7,643.80 lakhs, up from ₹4,943.46 lakhs in FY25. For the quarter ended March 31, 2026, consolidated profit after tax was ₹2,517.44 lakhs.
The company also noted a change in its Earnings Per Share (EPS) calculation method, now aligning with Ind AS 33 by using Profit After Tax attributable to equity shareholders, with restated figures for prior periods. The auditors' report provided an unmodified opinion on the financial results.
What to do with a filing like this
Syncom Formulations (India) Limited filed this with the NSE as a statutory disclosure, categorised under quarterly results. It is a primary document, not a recommendation, and the desk marks it medium impact: worth reading, rarely worth acting on by itself.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Syncom Formulations (India) Limited. Read the original for the full detail.